Background Alzheimer's disease (AD) is a multifactorial disease, with ongoing amyloid and
tau accumulation, axonal damage and astrocytosis. Blood‐based biomarkers reflecting …

Background: To enhance the accuracy of clinical diagnosis for Alzheimer's disease (AD), pre-
mortem biomarkers have become increasingly important for diagnosis and for participant …

Background Alzheimer's disease (AD)-related tauopathy can be measured with CSF
phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between …

The biological definition of Alzheimer's disease using CSF biomarkers requires abnormal
levels of both amyloid (A) and tau (T). However, biomarkers and corresponding cutoffs may …

Background Despite the high sensitivity of cerebrospinal fluid (CSF) amyloid beta (Aβ) 42 to
detect amyloid pathology, the Aβ42/Aβ40 ratio (amyR) better estimates amyloid load, with …

Both plasma tau phosphorylated at threonine-181 (pTau181) and tau PET show potential for
detecting Alzheimer's disease (AD) pathology and predicting clinical progression. In this …

Abstract Background In Alzheimer's disease (AD), plasma amyloid beta (Aβ) 1‐42 and
phosphorylated tau (p‐tau) predict high amyloid status from Aβ positron emission …

Objective The objective of this study was to evaluate novel plasma p‐tau231 and p‐tau181,
as well as Aβ40 and Aβ42 assays as indicators of tau and Aβ pathologies measured with …

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with
Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging …

Differential diagnosis of AD is still a challenge due to overlapping features with other types
of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value …